Search results for "ORPHAN DRUG|Designated/Approved|Treatment of ALK-positive non-small cell lung cancer" in comments (approximate match)
Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Alectinib is spe...